Abstract: In the world of digital advertising, optimally allocating an advertisement campaign within a fixed pre-defined budget for an advertising duration aimed at maximizing number of conversions is very important for an advertiser. Embodiments of present disclosure provides a robust and easily generalizable method of optimal allocation of advertisement campaign by formulating it as a constrained Markov Decision Process (MDP) defined by agent state comprising user state and advertiser state, action space comprising a plurality of ad campaigns, state transition routine and a cumulative reward model which rewards maximum total conversions in an advertising duration. The cumulative reward model is trained in conjunction with a deep Q-network for solving the MDP to optimally allocate advertisement campaign for an advertising duration within a constrained budget.

Abstract: In the world of digital advertising, optimally allocating an advertisement campaign within a fixed pre-defined budget for an advertising duration aimed at maximizing number of conversions is very important for an advertiser. Embodiments of present disclosure provides a robust and easily generalizable method of optimal allocation of advertisement campaign by formulating it as a constrained Markov Decision Process (MDP) defined by agent state comprising user state and advertiser state, action space comprising a plurality of ad campaigns, state transition routine and a cumulative reward model which rewards maximum total conversions in an advertising duration. The cumulative reward model is trained in conjunction with a deep Q-network for solving the MDP to optimally allocate advertisement campaign for an advertising duration within a constrained budget.

Abstract: Among the various aspects of the present disclosure is the provision of OXTR chaperones and methods of use thereof. An aspect of the present disclosure provides for a method of increasing the display of oxytocin receptor (OXTR) on a plasma membrane in a cell of a subject comprising: administering an OXTR chaperone, wherein the OXTR chaperone increases OXTR on a cell surface. Another aspect of the present disclosure provides for a method of increasing or restoring oxytocin sensitivity in a subject comprising: administering an OXTR chaperone, wherein the OXTR chaperone increases OXTR on a cell surface. Yet another aspect of the present disclosure provides for a method of increasing the efficacy of oxytocin or synthetic oxytocin in a subject comprising: administering an OXTR chaperone, wherein the OXTR chaperone increases OXTR on a cell surface.

Abstract: The presently-disclosed subject matter includes methods for treating Alzheimer's disease in a subject. The subject can have Alzheimer's diseases, can be identified has being at risk for developing Alzheimer's disease, or both. The method can comprise administering a composition that includes a CD33 inhibitor, which may include a CD33 antibody. In some embodiments the composition can further comprise at least one additional component useful for treating Alzheimer's disease. The presently-disclosed subject matter also includes compositions and kits for treating Alzheimer's disease in a subject.